CM
FOLD

Crestline Management’s Amicus Therapeutics FOLD Stock Holding History

Crestline Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-123,222
Closed -$1.77M – 224
2017
Q4 		$1.77M Buy
123,222
+70,377
+133% +$967K 0.18% 46
2017
Q3 		$797K Buy
+52,845
New +$699K 0.11% 111
2017
Q2 		– Sell
-134,200
Closed -$957K – 147
2017
Q1 		$957K Buy
+134,200
New +$848K 0.18% 57

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Crestline Management's FOLD Position: Q1 2018 in Review

Crestline Management sold out of Amicus Therapeutics (FOLD) in Q1 2018, closing a stake of 123,222 shares — an estimated $1.77M sold.

Crestline Management first reported a position in FOLD in Q1 2017 and held it in 3 quarters. The position peaked at $1.77M in Q4 2017. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2018.

  • Crestline Management reported no remaining Amicus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Crestline Management sold 123,222 Amicus Therapeutics shares in Q1 2018, an estimated $1.77M.
  • Crestline Management first reported a position in Amicus Therapeutics in Q1 2017 and held it in 3 quarters.
  • Crestline Management's Amicus Therapeutics position peaked at $1.77M in Q4 2017.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2018.

Based on Crestline Management's 13F filing for Q1 2018, filed 15 May 2018.